Home/ Stocks/ TNGX

Tango Therapeutics, Inc.

TNGX XNAS

$27.07 -2.07 (-7.14%) ▼ 15-min delayed

Open

$28.71

High

$29.23

Low

$26.75

Volume

3.23M

Market Cap

$4.72B

About Tango Therapeutics, Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 137 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-45,514,000	$-0.32
FY 2025	$62.38M	$-101,594,000	$-0.87
Q3 2025	$53.81M	$15.88M	$0.14
Q2 2025	$3.18M	$-38,853,000	$-0.35

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for TNGX yet. Check out our latest market news or earnings calendar.

Get TNGX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Tango Therapeutics, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.